ClinicalTrials.gg
CompletedNCT02241629Updated May 7, 2015

Levo Phencynonate Hydrochloride for the Prevention of Seasickness

A Phase 2 interventional study of placebo and levo phencynonate hydrochloride in Motion Sickness, sponsored by Sihuan Pharmaceutical Holdings Group Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-07.

Sponsored by Sihuan Pharmaceutical Holdings Group Ltd. · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A double-blind, randomized, placebo controlled, multicenter, dose-finding phaseⅡclinical superiority study.

Read the detailed description

The trial is composed by 3 parts: 1) On-boat screening period for seasickness and safety tests will be evaluated in minus one day. 2) 4 weeks of washout period to eliminate the impact of voyage experience. 3) On-boat drug testing period. The subjects will be administered the drug before voyage. The seasickness symptoms will be evaluated during voyage. The safety test will be conducted before and after one day of on-boat testing.

02

Conditions studied

  • Motion Sickness

Browse trials for

Keywords

  • motion sickness
03

In context

Motion Sickness

50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.

This study's enrollment of 180 is above the median of 59 across 44 interventional studies indexed under Motion Sickness.

Browse Motion Sickness studies →

Lead sponsor

Sihuan Pharmaceutical Holdings Group Ltd. is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects fulfilling the diagnostic criteria for motion sickness
  • Have medical history for motion sickness
  • During screening, the severity of sea sickness is assessed as moderate or above according to sea sickness severity scale.
  • Adults for 18-55 years, male or female.
  • Agree to participate the study and can sign the ICF independently.

Exclusion criteria

Exclusion Criteria:

  • Be allergic to the study drug or be allergic constitution
  • , AST≥ 1.5 times of , Scr>ULN, or other clinical significant lab values.
  • Abnormal which is clinical significant judged by investigators, including: >normal range
  • Have medical history for urination disorder
  • Have headache, vertigo, dizziness or nsomnia caused by other diseases than motion sickness.
  • Have active gastrointestinal diseases or overweight (≥24kg/m2 )
  • Have internal ear disease which may disturb the evaluation of motion sickness.
  • Have glaucoma or posterior circulation ischemia
  • Have anxiety, depression or other mental disease that investigator considering inadaptable to participate the study.
  • Participated in other studies within the past 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    levo phencynonate hydrochloride 1mg

    levo phencynonate hydrochloride tablet 1mg

    Drug: placebo · Drug: levo phencynonate hydrochloride

  • Placebo comparator
    placebo

    Placebo

    Drug: placebo

  • Experimental
    levo phencynonate hydrochloride 2mg

    levo phencynonate hydrochloride 2mg

    Drug: levo phencynonate hydrochloride

Interventions

  • Drugplacebo

    placebo of levo phencynonate hydrochloride

  • Druglevo phencynonate hydrochloride

    levo phencynonate hydrochloride

06

What researchers measure

Primary outcomes

  1. the symptoms of seasickness

    Investigators should assess the symptoms of seasickness for subjects according to sea sickness severity scale.

    Time frame: Two hours of voyage

07

Study locations

1 site
  • Qingdao municipal hospital
    Qingdao, Shandong, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Dec 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2014
First posted
Sep 16, 2014
Start
Aug 2014
Primary completionActual
Dec 2014
CompletionActual
Feb 2015
Last update
May 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02241629
Responsible party
Sponsor
First posted
Sep 16, 2014
Start date
Aug 2014
Primary completion
Dec 2014
Completion
Feb 2015
Last update
May 7, 2015

Study contacts

Weiguo Xue
principal investigator · Qingdao Municipal Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion